Raptor Pharmaceutical Corp, which develops drugs that treat orphan diseases, is in discussions with investment banks to hire a financial adviser to explore a potential sale, according to people familiar with the matter.
The move may not lead to a sale, the people said this week, asking not to be identified because the deliberations are confidential. Raptor did not respond to a request for comment.
By Carl O’Donnell
BD’s new company will have the freedom to expand its portfolio of tools and technologies for the chronic care of diabetes.
The Belgian biotech is pulling out of metabolic diseases and osteoarthritis R&D to focus on its core therapeutic areas.
Catalent will use its new facility for commercial production of plasmid DNA, used to make a range of biologics, including viral vectors, mRNA and cell therapies.